1201192-62-2

Basic information

• Product Name: 1-tert-Butyl 3-methyl 4-methylpiperidine-1,3-dicarboxylate
• Synonyms: 1-tert-Butyl 3-methyl 4-methylpiperidine-1,3-dicarboxylate;1,3-Piperidinedicarboxylic acid, 4-methyl-, 1-(1,1-dimethylethyl) 3-methyl ester
• CAS NO: 1201192-62-2
• Molecular Formula: C13H23NO4
• Molecular Weight: 257.32602
• Mol File: 1201192-62-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-tert-Butyl 3-methyl 4-methylpiperidine-1,3-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-Butyl 3-methyl 4-methylpiperidine-1,3-dicarboxylate(1201192-62-2)
• EPA Substance Registry System: 1-tert-Butyl 3-methyl 4-methylpiperidine-1,3-dicarboxylate(1201192-62-2)

Safety Data

• Hazardous Substances Data: 1201192-62-2(Hazardous Substances Data)

Usage

Chemical class

piperidine derivatives

Common uses

synthesis of pharmaceuticals and agrochemicals

Potential applications

local anesthetic, analgesic, treatment of neurodegenerative diseases, and cancer research

Unique feature

specific molecular structure

Importance

valuable building block for new drug development

Versatility

diverse applications in medicinal chemistry

Upstream product

• 94015-05-1 4-methylpyridine-3-carboxylic acid hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3430-22-6 3-Bromo-4-methylpyridin 
• 33402-75-4 4-methylnicotinic acid methyl ester 
• 3222-50-2 4-methylnicotinic acid 
• 908244-98-4 methyl 4-methylpiperidine-3-carboxylate 

Downstream Products

• 1271810-25-3 trans 1-(tert-butoxycarbonyl)-4-methylpiperidine-3-carboxylic acid 
• 1207853-61-9 trans-racemic tert-butyl 3-amino-4-methylpiperidine-1-carboxylate 
• 1009376-52-6 1-(tert-butoxycarbonyl)-4-methylpiperidine-3-carboxylic acid 

Relevant articles and documents

9-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): (I), and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS PDE2 INHIBITORS

The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.